[1]
|
Garcia Sar, D., Montes-Bayon, M., Aguado Ortiz, L., Blanco-Gonzalez, E., Sierra, L.M. and Sanz-Medel, A. (2008) In Vivo Detection of DNA Adducts Induced by Cisplatin Using Capillary HPLC-ICP-MS and Their Correlation with Genotoxic Damage in Dorsophilia melanogaster. Analytical and Bioanalytical Chemistry, 390, 37-44. https://doi.org/10.1007/s00216-007-1634-z
|
[2]
|
Bahadir, A., Ceyhan, A., Öz Gergin, Ö., Yalçin, B., ülger, M., Özyazgan, T.M. and Yay, A. (2018) Protective Effects of Curcmin and Beta Carotene on Cisplatin-Induced Cardiotoxicity: A Experimental Rat Model. The Anatolian Journal of Cardiology, 19, 213-221. https://doi.org/10.14744/AnatolJCardiol.2018.53059
|
[3]
|
Ma, J., Wang, Q., Yang, X., Hao, W., Huang, Z., Zhang, J., Wang, X. and Wang, P. (2016) The Glycosylated Platinum(IV) Prodrugs Demonstrated Significant Therapeutic Efficacy in Cancer Cells and Minimized Side-Effects. Dalton Transactions, 45, 11830-11838. https://doi.org/10.1039/C6DT02207C
|
[4]
|
Tromp, R.A., Stella, S.G., Marco, Timmers, C., van Zutphen, S., van der Marel, G.A., Overkleeft, H.S., van Boom, J.H. and Reedijk, J. (2004) The Beta-Glucuronyl-Based Prodrug Strategy Allows for Its Application on Beta-Glucuronyl-Platinum Conjugates. Bioorganic & Medicinal Chemistry Letters, 14, 4273-4279. https://doi.org/10.1016/j.bmcl.2004.06.015
|
[5]
|
Deng, D., Xu, C., Sun, P., Wu, J., Yan, C., Hu, M. and Yan, N. (2014) Crystal Structure of the Human Glucose Transporter GLUT1. Nature, 510, 121-125.
https://doi.org/10.1038/nature13306
|
[6]
|
Amable, L. (2016) Cisplatin Resistance and Opportunities for Precision Medicine. Pharmacological Research, 106, 27-36. https://doi.org/10.1016/j.phrs.2016.01.001
|
[7]
|
Chen, S.J., Kuo, C.C., Pan, H.Y., Tsou, T.C., Yeh, S.C. and Chang, J.Y. (2015) Mechanistic Basis of a Combination D-Penicillamine and Platinum Drugs Synergistically Inhibits Tumor Growth in Oxaliplatin-Resistant Human Cervical Cancer Cells in Vitro and in Vivo. Biochemical Pharmacology, 95, 28-37.
https://doi.org/10.1016/j.bcp.2015.03.006
|
[8]
|
Chen, S.J., Kuo, C.C., Pan, H.Y., Tsou, T.C., Yeh, S.C. and Chang, J.Y. (2016) Desferal Regulates hCtr1 and Transferrin Receptor Expression through Sp1 and Exhibits Synergistic Cytotoxicity with Platinum Drugs in Oxaliplatin-Resistant Human Cervical Cancer Cells in Vitro and in Vivo. Oncotarget, 7, 49310-49321.
https://doi.org/10.18632/oncotarget.10336
|
[9]
|
Lai, Y.H., Kuo, C., Kuo, M.T. and Chen, H.H.W. (2018) Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis. International Journal of Molecular Sciences, 19, Article No. 1486. https://doi.org/10.3390/ijms19051486
|
[10]
|
Öhrvik, H., Logeman, B., Turk, B., Reinheckel, T. and Thiele, D.J. (2016) Cathepsin Protease controls Copper and Cisplatin Accumulation via Cleavage of the Ctr1 Metal-Binding Ectodomain. Journal of Biological Chemistry, 291, 13905-13916.
https://doi.org/10.1074/jbc.M116.731281
|
[11]
|
Lee, Y.Y., Choi, C.H., Do, I.G., Song, S.Y., Lee, W., Park, H.S., Song, T.J., Kim, M.K., Kim, T.J., Lee, J.W., et al. (2011) Prognostic Value of the Copper Transporters, CTR1 and CTR2, in Patients with Ovarian Carcinoma Receiving Platinum-Based Chemotherapy. Gynecologic Oncology, 122, 361-365.
https://doi.org/10.1016/j.ygyno.2011.04.025
|
[12]
|
Yoshida, H., Teramae, M., Yamauchi, M., Fukuda, T., Yasui, T., Sumi, T., Honda, K. and Ishiko, O. (2013) Association of Copper Transporter Expression with Platinum Resistance in Epithelial Ovarian Cancer. Anticancer Research, 33, 1409-1414.
|
[13]
|
Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., Sugimachi, K. and Kuwano, M. (2015) Increased Expression of an ATP-Binding Cassette Superfamily Transporter, Multidrug Resistance Protein 2, in Human Colorectal Carcinomas. Clinical Cancer Research, 6, 2401-2407.
|
[14]
|
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) Role of Multidrug Resistance Protein 2 (MRP2) in Chemoresistance and Clinical Outcome in Oesophageal Squamous Cell Carcinoma. British Journal of Cancer, 104, 707-713.
https://doi.org/10.1038/sj.bjc.6606071
|
[15]
|
Hirano, T., Kato, H., Maeda, M., Gong, Y., Shou, Y., Nakamura, M., Maeda, J., Yashima, K., Kato, Y., Akimoto, S., et al. (2005) Identification of Postoperative Adjuvant Chemotherapy Responders in Non-Small Cell Lung Cancer by Novel Biomarker. International Journal of Cancer, 117, 460-468.
https://doi.org/10.1002/ijc.21172
|
[16]
|
Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., Matsuda, T. and Saijo, N. (1991) Metallothionein Content Correlates with the Sensitivity of Human Small Cell Lung Cancer Cell Lines to Cisplatin. Cancer Research, 51, 3237-3242.
|
[17]
|
Dasari, S. and Tchounwou, P.B. (2014) Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. European Journal of Pharmacology, 740, 364-378.
https://doi.org/10.1016/j.ejphar.2014.07.025
|
[18]
|
Rocha, C.R.R., Silva, M.M., Quinet, A., Cabral-Neto, J.B. and Menck, C.F.M. (2018) DNA Repair Pathways and Cisplatin Resistance: An Intimate Relationship. Clinics, 73, Article No. e478s. https://doi.org/10.6061/clinics/2018/e478s
|
[19]
|
Deloia, J.A., Bhagwat, N.R., Darcy, K.M., Strange, M., Tian, C., Nuttall, K., Krivak, T.C. and Niedernhofer, L.J. (2012) Comparison of ERCC1/XPF Genetic Variation, mRNA and Protein Levels in Women with Advanced Stage Ovarian Cancer Treated with Intraperitoneal Platinum. Gynecologic Oncology, 126, 448-454.
https://doi.org/10.1016/j.ygyno.2012.05.006
|
[20]
|
Li, Z., Qing, Y., Guan, W., Li, M., Peng, Y., Zhang, S., Xiong, Y. and Wang, D. (2014) Predictive Value of APE1, BRCA1, ERCC1 and TUBB3 Expression in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Platinum-Paclitaxel Chemotherapy. Cancer Chemotherapy and Pharmacology, 74, 777-786. https://doi.org/10.1007/s00280-014-2562-1
|
[21]
|
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J.R., Andreas, S., Kortsik, C., Serke, M., Wolf, M., Neuser, P., Reuss, A., et al. (2018) ERCC1 Assessment in Upfront Treatment with and without Cisplatin-Based Chemotherapy in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer. Medical Oncology, 35, Article No. 106. https://doi.org/10.1007/s12032-018-1169-5
|
[22]
|
Zhang, Z., Jiang, C. and Hu, L. (2014) Low Expression of Excision Repair Cross-Complementation Group-1 Protein Predicts Better Outcome in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy. Tumori Journal, 100, 328-332.
|
[23]
|
Huang, J., Zhou, Y., Zhang, H., Qu, T., Mao, Y., Zhu, H., Quan, L., Xing, P., Wang, J., He, J., et al. (2013) A Phase II Study of Biweekly Paclitaxel and Cisplatin Chemotherapy for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: ERCC1 Expression Predicts Response to Chemotherapy. Medical Oncology, 30, Article No. 343. https://doi.org/10.1007/s12032-012-0343-4
|
[24]
|
Ryu, H., Song, I.C., Choi, Y.S., Yun, H.J., Jo, D.Y., Kim, J.M., Ko, Y.B. and Lee, H.J. (2017) ERCC1 Expression Status Predicts the Response and Survival of Patients with Metastatic or Recurrent Cervical Cancer Treated via Platinum-Based Chemotherapy. Medicine, 96, e9402. https://doi.org/10.1097/MD.0000000000009402
|
[25]
|
Ma, X., Huang, J., Du, W., Zhuo, H., Zhang, J., Shi, C. and Liu, L. (2015) ERCC1 Plays an Important Role in Predicting Survival Outcomes and Treatment Response for Patients with HNSCC: A Meta-Analysis. Oral Oncology, 51, 483-492.
https://doi.org/10.1016/j.oraloncology.2015.02.094
|
[26]
|
Hwang, I.G., Jang, J.S., Do, J.H., Kang, J.H., Lee, G.W., Oh, S.Y., Kwon, H.C., Jun, H.J., Lim, H.Y., Lee, S., et al. (2011) Different Relation between ERCC1 Overexpression and Treatment Outcomes of Two Platinum Agents in Advanced Biliary Tract Adenocarcinoma Patients. Cancer Chemotherapy and Pharmacology, 8, 935-944.
https://doi.org/10.1007/s00280-011-1558-3
|
[27]
|
Shen, D.W., Pouliot, L.M., Hall, M.D., Gottesman, M.M. (2012) Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacological Reviews, 64, 706-721.
https://doi.org/10.1124/pr.111.005637
|
[28]
|
Arts, H.J., Hollema, H., Lemstra, W., Willemse, P.H., De Vries, E.G., Kampinga, H.H. and Van der Zee, A.G. (1999) Heatshock-Protein-27 (hsp27) Expression in Ovarian Carcinoma: Relation in Response to Chemotherapy and Prognosis. International Journal of Cancer, 84, 234-238.
https://doi.org/10.1002/(SICI)1097-0215(19990621)84:3%3C234::AID-IJC6%3E3.0.CO;2-9
|
[29]
|
Liu, J.R., Opipari, A.W., Tan, L., Jiang, Y., Zhang, Y., Tang, H. and Nunez, G. (2002) Dysfunctional Apoptosome Activation in Ovarian Cancer: Implications for Chemoresistance. Cancer Research, 62, 924-931.
|
[30]
|
Vargas-Roig, L.M., Gago, F.E., Tello, O., Aznar, J.C. and Ciocca, D.R. (1998) Heat Shock Protein Expression and Drug Resistance in Breast Cancer Patients Treated with Induction Chemotherapy. International Journal of Cancer, 79, 468-475.
https://doi.org/10.1002/(SICI)1097-0215(19981023)79:5%3C468::AID-IJC4%3E3.0.CO;2-Z
|
[31]
|
Belfi, C.A., Chatterjee, S., Gosky, D.M., Berger, S.J. and Berger, N.A. (1999) Increased Sensitivity of Human Colon Cancer Cells to DNA Cross-Linking Agents after GRP78 Up-Regulation. Biochemical and Biophysical Research Communications, 257, 361-368. https://doi.org/10.1006/bbrc.1999.0472
|
[32]
|
Huang, T.G., Ip, S.M., Yeung, W.S. and Ngan, H.Y. (2000) Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 Expression in Cervical Cancer Cell Lines Transfected with a p53 Expressing Adenovirus. European Journal of Cancer, 36, 249-256.
https://doi.org/10.1016/S0959-8049(99)00247-6
|
[33]
|
Brozovic, A., Simaga, S. and Osmak, M. (2000) Induction of Heat Shock Protein 70 in Drug-Resistant Cells by Anticancer Drugs and Hyperthermia. Neoplasma, 48, 99-103.
|
[34]
|
Skvortsov, S., Dudas, J., Eichberger, P., Witsch-Baumgartner, M., Loeffler-Ragg, J., Pritz, C., Schartinger, V.H., Maier, H., Hall, J., Debbage, P., Riechelmann, H., Lukas, P. and Skvortsova, I. (2014) Rac1 as a Potential Therapeutic Target for Chemo-Radioresistant Head and Neck Squamous Cell Carcinomas (HNSCC). British Journal of Cancer, 110, 2677-2687. https://doi.org/10.1038/bjc.2014.221
|
[35]
|
Shen, D.W., Liang, X.J., Gawinowicz, M.A. and Gottesman, M.M. (2004) Identification of Cytoskeletal [14C] Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. Molecular Pharmacology, 66, 789-793. https://doi.org/10.1124/mol.66.4.789
|
[36]
|
Kurayoshi, M., Yamamoto, H., Izumi, S. and Kikuchi, A. (2007) Post-Translational Palmitoylation and Glycosylation of Wnt5a Are Necessary for Its Signaling. Biochemical Journal, 15, 515-523. https://doi.org/10.1042/BJ20061476
|
[37]
|
Hanaki, H., Yamamoto, H., Sakane, H., Matsumoto, S., Ohda, H., Sato, A. and Kikuchi, A. (2012) An Anti-Wnt5a Antibody Suppresses Metastasis of Gastric Cancer Cells in Vivo by Inhibiting Receptor-Mediated Endocytosis. Molecular Cancer Therapeutics, 11, 298-307. https://doi.org/10.1158/1535-7163.MCT-11-0682
|
[38]
|
Finne, J. and Mäkelä, P.H. (1985) Cleavage of the Polysialosyl Units of Brain Glycoproteins by a Bacteriophage Endosialidase. Involvement of a Long Oligosaccharide Segment in Molecular Interactions of Polysialic Acid. Journal of Biological Chemistry, 260, 1265-1270. https://doi.org/10.1016/S0021-9258(20)71238-X
|
[39]
|
Michon, F., Brisson, J.R. and Jennings, H.J. (1987) Conformational Differences between Linear Alpha (2-8)-Linked Homosialooligosaccharides and the Epitope of the Group B Meningococcal Polysaccharide. Biochemistry, 26, 8399-8405.
https://doi.org/10.1021/bi00399a055
|
[40]
|
Kabat, E.A., Liao, J., Osserman, E.F., Gamian, A., Michon, F. and Jennings, H.J. (1988) The Epitope Associated with the Binding of the Capsular Polysaccharide of the Group B. meningococcus and of Escherichia coli K1 to a Human Monoclonal Macroglobulin, IgMNOV. Journal of Experimental Medicine, 168, 699-711.
https://doi.org/10.1084/jem.168.2.699
|
[41]
|
Livingston, B.D., Jacobs, J.L., Glick, M.C. and Troy, F.A. (1988) Extended Polysialic Acid Chains (n > 55) in Glycoproteins from Human Neuroblastoma Cells. Journal of Biological Chemistry, 263, 9443-9448.
https://doi.org/10.1016/S0021-9258(19)76560-0
|
[42]
|
Muller, D., Stoppini, L., Wang, C. and Kiss, J.Z. (1994) A Role for Polysialylated Neural Cell Adhesion Molecule in Lesion-Induced Sprouting in Hippocampal Organotypic Cultures. Neuroscience, 61, 441-445.
https://doi.org/10.1016/0306-4522(94)90424-3
|
[43]
|
Vutskits, L., Djebbara-Hannas, Z., Zhang, H., Paccaud, J.P., Durbec, P., Rougon, G., Muller, D. and Kiss, J.Z. (2001) PSA-NCAM Modulates BDNF-Dependent Survival and Differentiation of Cortical Neurons. European Journal of Neuroscience, 13, 1391-1402. https://doi.org/10.1046/j.0953-816x.2001.01516.x
|
[44]
|
Moloney, D.J. and Haltiwanger, R.S. (1999) The O-Linked Fucose Glycosylation Pathway: Identification and Characterization of a Uridine Diphosphoglucose: Fucose-1,3-glucosyltransferase Activity from Chinese Hamster Ovary Cells. Glycobiology, 9, 679-687. https://doi.org/10.1093/glycob/9.7.679
|
[45]
|
David, B. (2019) Advances in Carbohydrate Chemistry and Biochemistry. Elsevier, Amsterdam, 78.
|
[46]
|
Ji, J., Li, J., Holmes, L.M., Burgin, K.E., Yu, X., Wagner, T.E. and Wei, Y. (2002) Glycoinositol Phospholipid-Anchored Interleukin 2 but Not Secreted Interleukin 2 Inhibits Melanoma Tumor Growth in Mice. Molecular Cancer Therapeutics, 1, 1019-1024.
|